803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

BackgroundOver 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed little in the last 30 years, highlighting the need for therapy innovation. T cells engineered to express a T cell receptor (TCR) targeting proteins uniquely overe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal for immunotherapy of cancer Jg. 11; H. Suppl 1; S. A902
Hauptverfasser:	Anderson, Kristin G, Su, Yapeng, Burnett, Madison G, Bates, Breanna M, Suarez Gutierrez, Magdalia L, Ruskin, Susan L, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BMJ Publishing Group Ltd 01.11.2023 BMJ Publishing Group LTD BMJ Publishing Group
Schlagworte:	Cancer therapies Immunotherapy Lymphocytes Ovarian cancer Regular and Young Investigator Award Abstracts T cell receptors Tumors
ISSN:	2051-1426
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!